Prolonged Bleeding: What Could Be Causing It

Defining Prolonged Bleeding in Clinical Terms

Prolonged bleeding is not a diagnosis. It is a symptom that signals dysfunction somewhere along the hemostatic pathway, from initial platelet plug formation through the coagulation cascade to clot stabilization. A systematic approach to the differential prevents missed diagnoses and delayed treatment.

Normal hemostasis involves three overlapping phases: primary hemostasis (platelet adhesion and aggregation), secondary hemostasis (the coagulation cascade generating fibrin), and fibrinolysis (controlled clot breakdown). A defect at any stage can produce bleeding that persists longer than expected. The 2022 International Society on Thrombosis and Haemostasis (ISTH) guidelines define clinically significant bleeding using the ISTH bleeding assessment tool, which scores bleeding symptoms across multiple sites to distinguish pathological from incidental findings 1. Skin bleeding, such as bruising or petechiae, suggests platelet or vascular wall problems. Deep tissue or joint bleeding points toward coagulation factor deficiency. Mucocutaneous bleeding (gums, nosebleeds, heavy periods) can indicate either category. The patient's age, sex, medication list, family history, and the specific anatomic site all shape the differential. In a 2020 BMJ Best Practice review, the authors noted that "a structured bleeding history using a validated bleeding assessment tool is the single most cost-effective step in evaluating unexplained hemorrhage" 2.

Inherited Bleeding Disorders

Von Willebrand disease (VWD) stands as the most prevalent inherited cause of prolonged bleeding, affecting approximately 1 in 100 people worldwide, though symptomatic disease is less common at roughly 1 in 1,000 3.

VWD results from quantitative or qualitative defects in von Willebrand factor, a glycoprotein required for platelet adhesion to injured vessel walls and for stabilizing factor VIII in circulation. Type 1 (partial quantitative deficiency) accounts for 70% to 80% of cases. Type 2 variants (2A, 2B, 2M, 2N) involve qualitative defects. Type 3, the rarest and most severe form, involves near-complete absence of the protein. Patients typically present with mucocutaneous bleeding: prolonged nosebleeds, easy bruising, heavy menstrual periods, and excessive bleeding after dental work or surgery 3.

Hemophilia A (factor VIII deficiency) and hemophilia B (factor IX deficiency) follow X-linked inheritance patterns, making them far more common in males. Hemophilia A occurs in approximately 1 in 5,000 male births 4. Severe hemophilia (factor level <1%) produces spontaneous joint and muscle bleeding. Mild hemophilia may go undetected until a surgical challenge or major trauma reveals the bleeding tendency. Less common inherited disorders include factor VII deficiency, factor XI deficiency (particularly prevalent in Ashkenazi Jewish populations), and rare fibrinogen disorders. Platelet function disorders such as Glanzmann thrombasthenia and Bernard-Soulier syndrome affect primary hemostasis and cause mucocutaneous bleeding patterns similar to VWD.

Medication-Induced Prolonged Bleeding

Prescription and over-the-counter medications represent the most frequent acquired cause of prolonged bleeding in clinical practice. Any patient presenting with new or worsening bleeding should have their medication list reviewed line by line.

Anticoagulants directly inhibit the coagulation cascade. Warfarin blocks vitamin K-dependent factors (II, VII, IX, X). Direct oral anticoagulants (DOACs) target either thrombin (dabigatran) or factor Xa (rivarelbaan, apixaban, edoxaban). A 2019 analysis of the ARISTOTLE trial data showed that major bleeding occurred in 2.13% per year of patients on apixaban versus 3.09% per year on warfarin 5. Antiplatelet agents (aspirin, clopidogrel, prasugrel, ticagrelor) impair platelet aggregation. Dual antiplatelet therapy after coronary stenting carries a major bleeding rate of approximately 1.5% to 3.5% per year depending on the combination and clinical context 6.

NSAIDs (ibuprofen, naproxen, diclofenac) reversibly inhibit cyclooxygenase and impair platelet function for the duration of drug activity. Aspirin irreversibly acetylates COX-1, affecting platelets for their full 7- to 10-day lifespan. SSRIs reduce platelet serotonin stores and have been associated with a 1.4- to 1.7-fold increased risk of upper gastrointestinal bleeding, particularly when combined with NSAIDs 7. Fish oil supplements at high doses (above 3 g/day of EPA+DHA), herbal supplements including ginkgo biloba, garlic, and ginger, and even high-dose vitamin E can each contribute to bleeding tendency. Dr. Adam Cuker, a hematologist at the University of Pennsylvania, has stated that "the combination of an anticoagulant with an antiplatelet agent and an NSAID creates a 'triple threat' that dramatically increases hemorrhagic risk, and this combination is more common than clinicians realize" 8.

Hormonal and Gynecological Causes

Heavy menstrual bleeding (HMB), defined as menstrual blood loss exceeding 80 mL per cycle or periods lasting longer than 7 days, affects roughly 25% of reproductive-age women and is among the most common reasons for gynecology referrals 9.

Uterine fibroids (leiomyomas) are the most prevalent structural cause of HMB. A systematic review found that 27% to 54% of women with fibroids reported heavy bleeding, with submucosal fibroids carrying the highest risk due to their distortion of the endometrial cavity 10. Endometrial polyps, adenomyosis, and endometrial hyperplasia each contribute to abnormal uterine bleeding through distinct mechanisms. The International Federation of Gynecology and Obstetrics (FIGO) PALM-COEIN classification system organizes the causes of abnormal uterine bleeding into structural (Polyp, Adenomyosis, Leiomyoma, Malignancy) and non-structural (Coagulopathy, Ovulatory dysfunction, Endometrial, Iatrogenic, Not yet classified) categories 11.

Ovulatory dysfunction, commonly seen in polycystic ovary syndrome (PCOS) and during the perimenopausal transition, leads to unopposed estrogen stimulation of the endometrium. Without progesterone-mediated stabilization from ovulation, the endometrial lining grows irregularly and sheds in a prolonged, unpredictable fashion. Thyroid disorders, both hypothyroidism and hyperthyroidism, can disrupt the menstrual cycle and produce prolonged bleeding. Approximately 20% to 25% of women presenting with HMB will have an underlying coagulopathy, most commonly VWD, making coagulation screening an important step in the evaluation 12.

Liver Disease and Coagulopathy

The liver synthesizes virtually all procoagulant and anticoagulant factors, fibrinolytic proteins, and thrombopoietin (the hormone that drives platelet production). Chronic liver disease produces a complex hemostatic defect that is neither purely pro-bleeding nor purely pro-clotting, though prolonged bleeding is a prominent clinical feature.

In cirrhosis, reduced synthesis of factors II, V, VII, IX, X, and XI leads to prolongation of PT/INR and aPTT. Thrombocytopenia in liver disease has multiple contributors: portal hypertension causing splenic sequestration, decreased thrombopoietin production, and bone marrow suppression from alcohol or hepatitis viruses. Approximately 64% to 84% of patients with cirrhosis have thrombocytopenia 13. Dysfibrinogenemia (qualitatively abnormal fibrinogen) occurs in up to 80% of patients with significant hepatocellular disease 14. Hyperfibrinolysis, from impaired hepatic clearance of tissue plasminogen activator, adds another layer of bleeding risk. The American Association for the Study of Liver Diseases (AASLD) recommends against using INR alone to assess bleeding risk in cirrhotics, since the test only measures procoagulant factor activity and fails to capture the simultaneous reduction in natural anticoagulants 14.

Renal Disease and Uremic Bleeding

Chronic kidney disease (CKD) and acute kidney injury both impair hemostasis through mechanisms distinct from liver disease. Uremic toxins interfere with platelet-vessel wall interactions and platelet aggregation.

The uremic platelet defect involves multiple pathways: reduced von Willebrand factor-mediated adhesion, impaired thromboxane A2 generation, increased nitric oxide and prostacyclin production by the endothelium, and the effect of uremic toxins (guanidinosuccinic acid, phenolic acids) on platelet signaling. Anemia compounds the problem by reducing red blood cell mass, which normally pushes platelets toward the vessel wall (a phenomenon called rheological platelet margination). Clinical manifestations include prolonged bleeding time, easy bruising, gastrointestinal bleeding, and excessive surgical bleeding. Maintaining hemoglobin above 10 g/dL with erythropoiesis-stimulating agents and correcting uremia with adequate dialysis are the primary strategies. Desmopressin (DDAVP) provides a temporary hemostatic boost by releasing stored von Willebrand factor and factor VIII, with an effect that lasts 6 to 12 hours. Conjugated estrogens offer a longer-acting option, with benefits lasting 1 to 2 weeks after a 5-day course 15.

Hematologic Malignancies and Disseminated Intravascular Coagulation

Bone marrow infiltration by leukemia, lymphoma, or myelodysplastic syndromes can cause thrombocytopenia and prolonged bleeding. Acute promyelocytic leukemia (APL) deserves special mention because it frequently presents with life-threatening DIC at diagnosis.

Disseminated intravascular coagulation (DIC) involves widespread activation of coagulation, consumption of platelets and clotting factors, and secondary fibrinolysis. The result is a paradoxical state of simultaneous clotting and bleeding. Sepsis is the most common trigger, responsible for 30% to 40% of DIC cases 16. Obstetric complications (placental abruption, amniotic fluid embolism), major trauma, and malignancy are other common causes. Laboratory findings include prolonged PT and aPTT, low fibrinogen, elevated D-dimer, thrombocytopenia, and the presence of schistocytes on peripheral blood smear. The ISTH DIC scoring system assigns points based on platelet count, fibrin-related markers, PT prolongation, and fibrinogen level, with a score of 5 or greater compatible with overt DIC 16. Treatment targets the underlying trigger. Platelet transfusion and cryoprecipitate may be needed for active bleeding.

Diagnostic Approach

The workup begins with three questions: Where is the bleeding? How long has it been happening? What medications does the patient take? The answers direct every subsequent test.

First-line laboratory evaluation includes a CBC with differential (platelet count, mean platelet volume), prothrombin time (PT/INR), activated partial thromboplastin time (aPTT), and fibrinogen level. An isolated prolonged aPTT with normal PT suggests factor VIII, IX, XI, or XII deficiency, or the presence of a lupus anticoagulant. An isolated prolonged PT with normal aPTT points toward factor VII deficiency or early warfarin effect. Prolongation of both PT and aPTT indicates common pathway involvement (factors X, V, II, fibrinogen), DIC, liver disease, or vitamin K deficiency 17.

If initial tests are normal but clinical suspicion remains high, second-line testing includes von Willebrand factor antigen and activity (ristocetin cofactor), factor XIII activity, platelet function testing (PFA-100 or platelet aggregometry), thrombin time, and a mixing study to differentiate factor deficiency from an inhibitor. For gynecological bleeding, pelvic ultrasound is the standard first imaging study. The American College of Obstetricians and Gynecologists (ACOG) recommends coagulation screening for all adolescents presenting with HMB and for adults with a suggestive bleeding history 18.

Treatment by Underlying Cause

There is no single treatment for prolonged bleeding. The correct intervention depends entirely on the etiology, and misidentifying the cause can lead to ineffective or harmful therapy.

For VWD, desmopressin (DDAVP) is first-line for type 1 and some type 2 variants. It releases stored VWF and factor VIII from endothelial cells. A test dose with VWF level measurement confirms responsiveness before planned procedures. For type 3 VWD or desmopressin-unresponsive patients, VWF-containing factor concentrates (Humate-P, Wilate) are used 3. Tranexamic acid, an antifibrinolytic, is effective as adjunctive therapy for mucocutaneous bleeding across multiple etiologies. For medication-induced bleeding, the approach varies by agent. Warfarin reversal uses vitamin K (IV for urgent situations, oral for non-urgent), with four-factor prothrombin complex concentrate (4F-PCC) for major bleeding. Idarucizumab reverses dabigatran. Andexanet alfa reverses factor Xa inhibitors, though its cost and limited availability restrict use.

For HMB without structural pathology, hormonal management with combined oral contraceptives, the levonorgestrel-releasing intrauterine system (LNG-IUS), or cyclic progestins is effective. The LNG-IUS reduces menstrual blood loss by a median of 86% at 3 months 19. Tranexamic acid reduces menstrual blood loss by 40% to 50% and can be used alongside hormonal methods 20. Surgical options for structural causes include hysteroscopic myomectomy or polypectomy and, for refractory cases, endometrial ablation or hysterectomy. For liver-associated coagulopathy, management focuses on the underlying liver disease. Vitamin K supplementation (10 mg IV) may help if nutritional deficiency contributes, though response is limited in advanced cirrhosis where the synthetic capacity of hepatocytes is the bottleneck.

When Prolonged Bleeding Is an Emergency

Certain patterns require immediate evaluation: bleeding that soaks through a pad or bandage every hour for two or more consecutive hours, bleeding accompanied by hemodynamic instability (heart rate above 100, systolic blood pressure below 90 mmHg), new onset of petechiae or purpura with fever, and postoperative bleeding exceeding expected volumes.

A platelet count below 10,000/μL carries a high risk of spontaneous intracranial hemorrhage and warrants urgent platelet transfusion regardless of the cause 21. Active bleeding in a patient on DOACs with hemodynamic compromise requires specific reversal agents rather than empiric fresh frozen plasma, which is ineffective against these drugs. Any patient with suspected DIC and active hemorrhage needs simultaneous resuscitation, laboratory evaluation, and treatment of the triggering condition. The 2023 ISTH guidelines on DIC management emphasize that "treating the underlying cause remains the cornerstone of DIC management; all supportive hemostatic measures are temporizing until the trigger is controlled" 16.

Patients with newly diagnosed thrombocytopenia, unexplained prolonged coagulation times, or recurrent bleeding episodes that lack an obvious explanation should be referred to a hematologist for specialized evaluation, including bone marrow biopsy if hematologic malignancy is suspected.